Patents by Inventor Shannon L. Okada

Shannon L. Okada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-CD40 antibodies and uses thereof
    Patent number: 11952427
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: March 15, 2022
    Date of Patent: April 9, 2024
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20220324989
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: March 15, 2022
    Publication date: October 13, 2022
    Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS, James William WEST
  • Anti-CD40 antibodies and uses thereof
    Patent number: 11306149
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: December 27, 2018
    Date of Patent: April 19, 2022
    Assignees: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens, James William West
  • ANTIBODIES TO CD40
    Publication number: 20210054091
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: November 6, 2020
    Publication date: February 25, 2021
    Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS
  • Nucleic acids encoding an anti-CD40 antibody
    Patent number: 10844130
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: November 24, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20200339700
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40 and comprise improved heavy and light chain variable regions that impart improved yield and reduced aggregation. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: December 27, 2018
    Publication date: October 29, 2020
    Applicants: Bristol-Myers Squibb Company, CytomX Therapeutics, Inc.
    Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS, James William WEST
  • ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY
    Publication number: 20200071412
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 5, 2020
    Applicants: The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • Antibodies to CD40 with enhanced agonist activity
    Patent number: 10479838
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: November 19, 2019
    Assignees: Bristol-Myers Squibb Company, The Rockefeller University
    Inventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • ANTIBODIES TO CD40
    Publication number: 20190248911
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: April 30, 2019
    Publication date: August 15, 2019
    Inventors: Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens
  • ANTIBODIES TO CD40
    Publication number: 20180142030
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: June 28, 2016
    Publication date: May 24, 2018
    Inventors: Bryan C. BARNHART, Brigitte DEVAUX, Aaron P. YAMNIUK, Shannon L. OKADA, Brenda L. STEVENS
  • ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY
    Publication number: 20160376371
    Abstract: Provided herein are agonistic antibodies, or antigen binding portions thereof, that bind to human CD40. Such antibodies optionally comprise Fc regions with enhanced specificity for Fc?RIIb. The invention also provides methods of treatment of cancer or chronic infection by administering the antibodies of the invention to a subject in need thereof.
    Type: Application
    Filed: June 28, 2016
    Publication date: December 29, 2016
    Applicants: The Rockefeller University, BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Jeffrey V. Ravetch, Rony Dahan, Bryan C. Barnhart, Brigitte Devaux, Aaron P. Yamniuk, Shannon L. Okada, Brenda L. Stevens